Faecal calprotectin: A biomarker of gastrointestinal disease in systemic sclerosis

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 50-57

  Andreasson K ^a   Scheja, A ^a   Saxne, T ^a   Ohlsson, B ^b   Hesselstrand, R ^a  

^a Department of Clinical Sciences ^*  (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Biomarkers; Calprotectin; Gastrointestinal tract; S100A9 protein; Systemic sclerosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; C REACTIVE PROTEIN; CALGRANULIN; CYANOCOBALAMIN; DOMPERIDONE; FOLIC ACID; HAPTOGLOBIN; IRON; LAXATIVE; MAGNESIUM; METOCLOPRAMIDE; OROSOMUCOID; PROTON PUMP INHIBITOR; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; CINERADIOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE PERSONNEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MINERAL DEFICIENCY; PATIENT REFERRAL; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; FECES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; SCLERODERMA, SYSTEMIC;

EID: 79959340763     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02340.x     Document Type: Article

References (34)

1. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008; 53: 1163-74.
2. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
3. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009; 48(Suppl. 3): iii36-9.
4. Manetti M, Neumann E, Müller A et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008; 58: 2866-73.
5. Khanna D, Hays RD, Maranian P et al. Reliability and validity of the University of California, Los Angeles Scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum 2009; 61: 1257-63.
6. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003; 21: S15-8.
7. Medsger TA, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
8. Pedersen J, Gao C, Egekvist H et al. Pain and biomechanical responses to distention of the duodenum in patients with systemic sclerosis. Gastroenterology 2003; 124: 1230-9.
9. Khanna D, Hays RD, Park GS et al. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007; 57: 1280-6.
10. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86: 557-66.
11. Shibata F, Miyama K, Shinoda F, Mizumoto J, Takano K, Nakagawa H. Fibroblast growth-stimulating activity of s100A9 (MRP-14). Eur J Biochem 2004; 271: 2137-43.
12. Haga H-J, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 1993; 2: 47-50.
13. Hammer HB, Ødegård S, Syversen SW et al. Calprotectin (a major S100 leukocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 150-4.
14. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
15. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
17. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
18. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
19. Svedlund J, Sjödin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
20. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 681-7.
21. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
22. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 2007; 26: 195-204.
23. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-8.
24. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in Inflammatory Bowel Disease. Inflamm Bowel Dis 2006; 12: 524-34.
25. van Rheenen PF, van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
26. Chulilla JAM, Colás MSR, Martín MG. Classification of anemia for gastroenterologists. World J Gastroenterol 2009; 15: 4627-37.
27. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis. Results from the Canadian scleroderma research group database. J Rheumatol 2010; 37: 2737-43.
28. Manz M, Burri E, Niederberger C, Rothen C, Beglinger C. Faecal calprotectin predicts upper gastrointestinal pathology [abstract]. Gastro 2009 UEGW/WCOG, London 2009; P0136. (accessed 21 June 2010).
29. Montalto M, Santoro L, Dalvai S et al. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis 2008; 26: 183-6.
30. Poullis A, Foster R, Mendall M. Proton pump inhibitors are associated with elevation of feacal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003; 15: 573-4.
31. Montalto M, Santoro L, Curigliano V et al. Faecal calprotectin concentrations in untreated celiac patients. Scand J Gastroenterol 2007; 42: 957-61.
32. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-5.
33. Jeffery J, Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010; 3: 259-63.
34. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82.